Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain drugs
Biotech
Vertex drops asset in acute pain after phase 2 fail
All three dose levels of Nav1.8 inhibitor VX-993 failed to improve pain intensity over a 48-hour period compared to placebo.
Darren Incorvaia
Aug 4, 2025 5:34pm
Latigo saddles up with $150M to advance non-opioid pain assets
Mar 17, 2025 5:00am
Tris' next-gen pain drug completes trio of clinical wins
Mar 6, 2025 8:30am
Undaunted Vertex closes in on FDA nod for non-opioid pain drug
Oct 28, 2024 5:00am
Polyrizon pays $3M for license to SciSparc's CB2R agonist
Aug 19, 2024 5:27am
Levicept's ex-Pfizer drug reduces osteoarthritis pain in ph. 2
Aug 6, 2024 1:00am
